RecruitingPhase 2NCT04301843
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Studying Neuroblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Giselle Sholler
- Principal Investigator
- Giselle Sholler, MDBeat Childhood Cancer
- Intervention
- Eflornithine(drug)
- Enrollment
- 131 target
- Eligibility
- 31 years · All sexes
- Timeline
- 2020 – 2033
Study locations (30)
- University of Alabama/Children's of Alabama, Birmingham, Alabama, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
- Rady Children's Hospital, San Diego, California, United States
- Connecticut Children's Hospital, Hartford, Connecticut, United States
- Arnold Palmer Hospital for Children, Orlando, Florida, United States
- St. Joseph's Children's Hospital, Tampa, Florida, United States
- Augusta University Health, Augusta, Georgia, United States
- University of Iowa, Iowa City, Iowa, United States
- Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine, Louisville, Kentucky, United States
- Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
- Children's Hospital and Clinics of Minnesota, Minneapolis, Minnesota, United States
- Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States
- Cardinal Glennon Children's Hospital, St Louis, Missouri, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
K C Pharmaceuticals Inc. · Beat NB Cancer Foundation · Team Parker for Life · USWM, LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04301843 on ClinicalTrials.govOther trials for Neuroblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07549321A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma PatientsRenaissance Pharma Ltd.
- RECRUITINGPHASE1, PHASE2NCT06625190Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsUniversity of Florida
- RECRUITINGPHASE1NCT07172958Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)Children's National Research Institute
- RECRUITINGPHASE2NCT07085338A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory NeuroblastomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT07399821An Imaging Study of Anti-GD2-800CW in Patients With NeuroblastomaPrincess Maxima Center for Pediatric Oncology
- RECRUITINGPHASE1NCT06995872Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory NeuroblastomaNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT06814496Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsUniversity of Arizona
- RECRUITINGPHASE1NCT07087002GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young AdultsStanford University